
HTG Molecular Diagnostics HTGM
Annual report 2022
added 03-30-2023
HTG Molecular Diagnostics Book Value 2011-2026 | HTGM
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value HTG Molecular Diagnostics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.39 M | 10.4 M | 14.5 M | 24 M | 21.1 M | -3.06 M | -5.59 M | 16.9 M | -24 M | -22.4 M | -18.3 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 24 M | -24 M | 1.71 M |
Quarterly Book Value HTG Molecular Diagnostics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 1.21 M | 5.57 M | 11.3 M | 10.4 M | 14.9 M | 18.4 M | 16.8 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 24 M | 24 M | 24 M | 24 M | 21.1 M | 21.1 M | 21.1 M | 21.1 M | -3.06 M | -3.06 M | -3.06 M | -3.06 M | -5.59 M | -5.59 M | -5.59 M | -5.59 M | 16.9 M | 16.9 M | 16.9 M | 16.9 M | -13.7 M | -13.7 M | -13.7 M | -13.7 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 24 M | -13.7 M | 8.42 M |
Book Value of other stocks in the Diagnostics research industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M | ||
|
Agilent Technologies
A
|
5.39 B | $ 115.62 | 0.06 % | $ 35.1 B | ||
|
Akumin
AKU
|
141 M | - | -17.87 % | $ 25.9 M | ||
|
Accelerate Diagnostics
AXDX
|
-22.3 M | - | -61.36 % | $ 2.46 M | ||
|
Co-Diagnostics
CODX
|
20.6 M | $ 1.65 | -1.2 % | $ 2.19 M | ||
|
Aspira Women's Health
AWH
|
-6.93 M | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
8.86 M | - | -13.05 % | $ 7.29 M | ||
|
Castle Biosciences
CSTL
|
456 M | $ 24.98 | 2.13 % | $ 694 M | ||
|
Chembio Diagnostics
CEMI
|
17.8 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
-1.45 M | - | - | $ 9.42 M | ||
|
CareDx, Inc
CDNA
|
303 M | $ 21.85 | 2.92 % | $ 1.16 B | ||
|
Illumina
ILMN
|
6.3 B | $ 128.52 | 0.5 % | $ 20.4 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
16.7 M | - | - | $ 562 M | ||
|
DermTech
DMTK
|
57.2 M | - | -11.32 % | $ 2.94 M | ||
|
Enzo Biochem
ENZ
|
56.1 M | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
2.4 B | - | - | $ 19.8 B | ||
|
Fulgent Genetics
FLGT
|
1.13 B | $ 15.6 | -4.35 % | $ 472 M | ||
|
Global Cord Blood Corporation
CO
|
4.88 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
132 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
16.4 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
548 M | - | 0.12 % | $ 80.1 M | ||
|
Lantheus Holdings
LNTH
|
1.09 B | $ 84.11 | -0.26 % | $ 5.68 B | ||
|
Charles River Laboratories International
CRL
|
3.21 B | $ 171.23 | 0.86 % | $ 8.49 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
1.32 B | - | - | $ 10.7 B | ||
|
Medpace Holdings
MEDP
|
459 M | $ 421.37 | 2.64 % | $ 12.2 B | ||
|
Guardant Health
GH
|
-99.3 M | $ 88.5 | -0.46 % | $ 11.1 B | ||
|
Koninklijke Philips N.V.
PHG
|
11 B | $ 27.54 | 0.25 % | $ 20 B | ||
|
Personalis
PSNL
|
203 M | $ 5.96 | -2.3 % | $ 353 M | ||
|
Heska Corporation
HSKA
|
422 M | - | - | $ 1.31 B | ||
|
Interpace Biosciences
IDXG
|
22.4 M | $ 1.93 | -2.08 % | $ 8.54 M | ||
|
Senseonics Holdings
SENS
|
61 M | $ 7.27 | 3.12 % | $ 303 M | ||
|
Motus GI Holdings
MOTS
|
2.69 M | - | -34.28 % | $ 263 K | ||
|
Soleno Therapeutics
SLNO
|
450 M | $ 52.75 | 0.06 % | $ 2.68 B | ||
|
QIAGEN N.V.
QGEN
|
6.15 B | - | - | $ 10.6 B | ||
|
Neogen Corporation
NEOG
|
2.07 B | $ 9.45 | -0.94 % | $ 2.05 B | ||
|
Biomerica
BMRA
|
4.1 M | $ 2.18 | 1.87 % | $ 5.01 M | ||
|
National Research Corporation
NRC
|
14 M | $ 17.11 | -0.7 % | $ 383 M | ||
|
Thermo Fisher Scientific
TMO
|
110 B | $ 468.04 | -0.36 % | $ 176 B | ||
|
ICON Public Limited Company
ICLR
|
9.52 B | $ 103.21 | 1.02 % | $ 8.51 B | ||
|
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 263.43 | -0.12 % | $ 21.9 B | ||
|
Trinity Biotech plc
TRIB
|
-35.2 M | $ 0.64 | -0.82 % | $ 61.9 M | ||
|
Celcuity
CELC
|
101 M | $ 125.68 | 3.84 % | $ 5.88 B | ||
|
Twist Bioscience Corporation
TWST
|
473 M | $ 61.0 | 0.1 % | $ 3.65 B | ||
|
OpGen
OPGN
|
7.38 M | - | -16.95 % | $ 1.54 M | ||
|
NeoGenomics
NEO
|
837 M | $ 8.61 | 3.86 % | $ 1.1 B | ||
|
Myriad Genetics
MYGN
|
368 M | $ 4.83 | 1.05 % | $ 447 M | ||
|
Natera
NTRA
|
706 M | $ 204.39 | 0.31 % | $ 20.1 B | ||
|
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 196.63 | 0.21 % | $ 21.8 B | ||
|
Invitae Corporation
NVTA
|
102 M | - | - | $ 21.2 M |